Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

TriSalus Life Sciences (TLSI) Accumulated Depreciation & Amortization (2022 - 2026)

TriSalus Life Sciences has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $135000.0 for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization fell 21.51% year-over-year to $135000.0; the TTM value through Mar 2026 reached $135000.0, down 21.51%, while the annual FY2025 figure was $626000.0, 15.86% down from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $135000.0 at TriSalus Life Sciences, down from $626000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $744000.0 in Q4 2024 and troughed at $135000.0 in Q1 2026.
  • A 5-year average of $426454.5 and a median of $398000.0 in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 71.86% in 2023 and later dropped 21.51% in 2026.
  • Year by year, Accumulated Depreciation & Amortization stood at $398000.0 in 2022, then skyrocketed by 71.86% to $684000.0 in 2023, then increased by 8.77% to $744000.0 in 2024, then dropped by 15.86% to $626000.0 in 2025, then crashed by 78.43% to $135000.0 in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for TLSI at $135000.0 in Q1 2026, $626000.0 in Q4 2025, and $500000.0 in Q3 2025.